The WG3 will be in charge of developing the Methodology and validation protocols of future urinary tract stents.


  1. The production of a validation protocol (design, control, guidance for medical devices) (M16).
  2. Tests via in-silico simulation, 3D-printing, Exvivo-Invivo assessment and Preclinical testing considerations (M24).

D3. Report on Comprehensive Methodology and Validation protocol on new stent designs, including scientific publications related to the WG3 of the Action (M24), with TS and STSM related to the WG3 of the Action (M24).

Leader: Sotir Stavridis
Vice-Leader: Niels-P. Buchholz